Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Maintenance in Platinum-Sensitive Relapsed Ovarian Cancer (Study 19)
NCT00753545Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing Olaparib with Placebo (2 arms). Primary endpoint: Progression Free Survival at 14 months. Started Aug 2008; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00753545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00753545.